HK1079426A1 - Use of ikappab kinase inhibitors for the treatment of pain - Google Patents

Use of ikappab kinase inhibitors for the treatment of pain

Info

Publication number
HK1079426A1
HK1079426A1 HK05111381.9A HK05111381A HK1079426A1 HK 1079426 A1 HK1079426 A1 HK 1079426A1 HK 05111381 A HK05111381 A HK 05111381A HK 1079426 A1 HK1079426 A1 HK 1079426A1
Authority
HK
Hong Kong
Prior art keywords
pain
treatment
kinase inhibitors
ikappab kinase
ikappab
Prior art date
Application number
HK05111381.9A
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1079426A1 publication Critical patent/HK1079426A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05111381.9A 2002-08-17 2005-12-12 Use of ikappab kinase inhibitors for the treatment of pain HK1079426A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (1)

Publication Number Publication Date
HK1079426A1 true HK1079426A1 (en) 2006-04-07

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111381.9A HK1079426A1 (en) 2002-08-17 2005-12-12 Use of ikappab kinase inhibitors for the treatment of pain

Country Status (34)

Country Link
EP (1) EP1531819B1 (hr)
JP (1) JP4504811B2 (hr)
KR (2) KR20110135428A (hr)
CN (1) CN100398107C (hr)
AR (1) AR043045A1 (hr)
AT (1) ATE418336T1 (hr)
AU (1) AU2003271555B2 (hr)
BR (1) BR0313555A (hr)
CA (1) CA2495455C (hr)
CO (1) CO5690585A2 (hr)
CR (1) CR7716A (hr)
CY (1) CY1108874T1 (hr)
DE (2) DE10237723A1 (hr)
DK (1) DK1531819T3 (hr)
EC (1) ECSP055609A (hr)
ES (1) ES2320118T3 (hr)
HK (1) HK1079426A1 (hr)
HR (1) HRP20050041B1 (hr)
IL (1) IL166780A (hr)
MA (1) MA27334A1 (hr)
MX (1) MXPA05001218A (hr)
MY (1) MY138059A (hr)
NO (1) NO334309B1 (hr)
OA (1) OA12907A (hr)
PL (1) PL212356B1 (hr)
PT (1) PT1531819E (hr)
RS (1) RS51878B (hr)
RU (1) RU2320338C2 (hr)
SI (1) SI1531819T1 (hr)
TN (1) TNSN05044A1 (hr)
TW (1) TWI325782B (hr)
UA (1) UA80837C2 (hr)
WO (1) WO2004022057A1 (hr)
ZA (1) ZA200500323B (hr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5790440B2 (ja) * 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104105483B (zh) * 2011-12-06 2017-03-22 赛诺菲 2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑羧酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺的晶体形式
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9968605B2 (en) * 2014-07-03 2018-05-15 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
KR20210032950A (ko) 2018-07-16 2021-03-25 노파르티스 아게 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769350B2 (en) * 1999-06-23 2004-01-22 Sanofi-Aventis Deutschland Gmbh Substituted benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
TW200417370A (en) 2004-09-16
NO334309B1 (no) 2014-02-03
OA12907A (en) 2006-10-13
CY1108874T1 (el) 2014-07-02
AU2003271555B2 (en) 2009-03-26
EP1531819B1 (de) 2008-12-24
RU2320338C2 (ru) 2008-03-27
TWI325782B (en) 2010-06-11
CA2495455A1 (en) 2004-03-18
PL373568A1 (en) 2005-09-05
RS51878B (sr) 2012-02-29
HRP20050041A2 (hr) 2006-04-30
JP4504811B2 (ja) 2010-07-14
TNSN05044A1 (en) 2007-05-14
WO2004022057A1 (de) 2004-03-18
RS20050070A (en) 2007-06-04
HRP20050041B1 (hr) 2013-07-31
ATE418336T1 (de) 2009-01-15
JP2005539053A (ja) 2005-12-22
IL166780A0 (en) 2006-01-15
AR043045A1 (es) 2005-07-13
PL212356B1 (pl) 2012-09-28
DE50310980D1 (de) 2009-02-05
MXPA05001218A (es) 2005-05-16
MY138059A (en) 2009-04-30
CN100398107C (zh) 2008-07-02
ECSP055609A (es) 2005-04-18
EP1531819A1 (de) 2005-05-25
CA2495455C (en) 2011-01-11
DE10237723A1 (de) 2004-07-08
KR20050058339A (ko) 2005-06-16
KR101119845B1 (ko) 2012-02-28
MA27334A1 (fr) 2005-05-02
DK1531819T3 (da) 2009-04-20
SI1531819T1 (sl) 2009-06-30
KR20110135428A (ko) 2011-12-16
ES2320118T3 (es) 2009-05-19
BR0313555A (pt) 2005-07-12
CO5690585A2 (es) 2006-10-31
CN1674899A (zh) 2005-09-28
PT1531819E (pt) 2009-02-18
CR7716A (es) 2008-11-25
RU2005107419A (ru) 2005-08-10
IL166780A (en) 2011-11-30
NO20051339L (no) 2005-05-03
UA80837C2 (uk) 2007-11-12
AU2003271555A1 (en) 2004-03-29
ZA200500323B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
HK1067945A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AU2003268424A8 (en) Treatment of pain by inhibition of p38 map kinase
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0211295D0 (en) Treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2003259074A8 (en) Gal3 antagonists for the treatment of neuropathic pain
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
PL372534A1 (en) The treatment of pain with ifendropil
HK1062806A1 (en) Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors
HUP0402664A3 (en) 2-indanylamino derivatives for the therapy of chronic pain
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
IL174968A0 (en) The use of ifenprodil in the treatment of pain
GB0211297D0 (en) Pain treatment
GB0325957D0 (en) The treatment of pain
GB0213870D0 (en) The treatment of pain conditions

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20060407: ¢71! SANOFI-AVENTIS DEUTSCHLAND GMBH - D-65929 FRANKFURT AM MAIN - GERMANY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160805